1. Early Failure of Frontline Rituximab-Containing Chemo-immunotherapy in Diffuse Large B Cell Lymphoma Does Not Predict Futility of Autologous Hematopoietic Cell Transplantation 
Mehdi Hamadani, Parameswaran N. Hari, Ying Zhang, Jeanette Carreras, Görgün Akpek, Mahmoud D. Aljurf, Ernesto Ayala, Veronika Bachanova, Andy I. Chen, Yi-Bin Chen, Luciano J. Costa, Timothy S. Fenske, César O. Freytes, Siddhartha Ganguly, Mark S. Hertzberg, Leona A. Holmberg, David J. Inwards, Rammurti T. Kamble, Edward J. Kanfer, Hillard M. Lazarus, David I. Marks, Taiga Nishihori, Richard Olsson, Nishitha M. Reddy, David A. Rizzieri, Bipin N. Savani, Melhem Solh, Julie M. Vose, Baldeep Wirk, David G. Maloney, Sonali M. Smith, Silvia Montoto, Wael Saber 
Biology of Blood and Marrow Transplantation 
Volume 20, Issue 11, Pages (November 2014)
DOI: /j.bbmt
Copyright © 2014 American Society for Blood and Marrow Transplantation Terms and Conditions

2. Figure 1
Autologous transplantation outcomes for DLBCL, relative to the timing of rituximab failure. (A) Cumulative incidence of NRM, (B) cumulative incidence of disease progression/relapse, (C) PFS, and (D) OS. LRF is indicated by interrupted curves; ERF, solid curves.
Biology of Blood and Marrow Transplantation  , DOI: ( /j.bbmt )
Copyright © 2014 American Society for Blood and Marrow Transplantation Terms and Conditions

3. Figure 2
(A) PFS and (B) OS of ERF DLBCL patients with primary refractory disease (solid curve), compared with DLBCL relapsing within 12 months of initial diagnosis (interrupted curve).
Biology of Blood and Marrow Transplantation  , DOI: ( /j.bbmt )
Copyright © 2014 American Society for Blood and Marrow Transplantation Terms and Conditions